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Abstract
Background: Monozygotic twins discordant for type 2 diabetes constitute an ideal model to study environmental
contributions to type 2 diabetic traits. We aimed to examine whether global DNA methylation differences exist in major
glucose metabolic tissues from these twins.
Methodology/Principal Findings: Skeletal muscle (n= 11 pairs) and subcutaneous adipose tissue (n= 5 pairs) biopsies were
collected from 53–80 year-old monozygotic twin pairs discordant for type 2 diabetes. DNA methylation was measured by
microarrays at 26,850 cytosine-guanine dinucleotide (CpG) sites in the promoters of 14,279 genes. Bisulfite sequencing was
applied to validate array data and to quantify methylation of intergenic repetitive DNA sequences. The overall intra-pair
variation in DNA methylation was large in repetitive (LINE1, D4Z4 and NBL2) regions compared to gene promoters (standard
deviation of intra-pair differences: 10% points vs. 4% points, P,0.001). Increased variation of LINE1 sequence methylation
was associated with more phenotypic dissimilarity measured as body mass index (r = 0.77, P= 0.007) and 2-hour plasma
glucose (r = 0.66, P= 0.03) whereas the variation in promoter methylation did not associate with phenotypic differences.
Validated methylation changes were identified in the promoters of known type 2 diabetes-related genes, including
PPARGC1A in muscle (13.966.2% vs. 9.064.5%, P= 0.03) and HNF4A in adipose tissue (75.263.8% vs. 70.563.7%, P,0.001)
which had increased methylation in type 2 diabetic individuals. A hypothesis-free genome-wide exploration of differential
methylation without correction for multiple testing identified 789 and 1,458 CpG sites in skeletal muscle and adipose tissue,
respectively. These methylation changes only reached some percentage points, and few sites passed correction for multiple
testing.
Conclusions/Significance: Our study suggests that likely acquired DNA methylation changes in skeletal muscle or adipose
tissue gene promoters are quantitatively small between type 2 diabetic and non-diabetic twins. The importance of
methylation changes in candidate genes such as PPARGC1A and HNF4A should be examined further by replication in larger
samples.
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Introduction
Type 2 diabetes (T2D) is a heterogeneous and complex disease
resulting from a combination of impaired pancreatic insulin
secretion and insulin resistance in tissues such as skeletal muscle,
adipose tissue, and liver. The etiology of tissue defects causing
T2D is multifactorial. Several gene polymorphisms have been
identified [1–8], which together with environmental factors such as
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an adverse fetal environment, aging and obesity increase the risk of
T2D [9–11].
Phenotypic discordance in monozygotic twins is traditionally
attributed to environmental factors distinct for each individual.
Therefore, paired analyses of monozygotic twins discordant for a
disease phenotype provide an excellent tool for examination of the
environmental contribution to the disease in question.
Epigenetics is traditionally referred to as heritable changes in
gene expression which are not due to any alteration in DNA
sequence. Besides being heritable, epigenetics is altered by
environmental factors and hence represents a potential mechanism
through which the environment may cause phenotypic variation
[12]. Two major classes of epigenetic modifications of the
chromatin exist: methylation of cytosine, mostly at cytosine-
guanine dinucleotides (CpG)s, and histone modifications, notably
acetylations and methylations. The gene promoter regions are rich
in CpG sites, forming CpG islands [13], and methylation of these
cytosines is thought to silence gene transcription [14,15]. Histone
modifications may result in both activation and silencing of genes
[16].
Dietary intervention [17,18] and exercise [19,20] have been
demonstrated to provoke epigenetic modulation in humans. We
previously investigated global differences in methylation of
repetitive intergenic DNA sequences and acetylation of histones
in young and elderly monozygotic twin pairs. Interestingly, each
pair of young twins had essentially similar epigenetic markings,
whereas intra-pair differences were substantial in elderly twins,
suggesting epigenetic changes to accumulate during life [21].
Therefore, epigenetics has been supposed to play a role in the
development of age-related diseases [22]. Data on the role of
epigenetics in T2D are still sparse, particularly in the glucose
metabolic tissues involved in the pathogenesis of insulin resistant
T2D. Increased methylation of PPARGC1A, encoding peroxisome
proliferator-activated receptor (PPAR)c co-activator 1a (PGC-1a),
was first reported in pancreatic islets from type 2 diabetic
individuals [23], and interestingly, similar T2D-related changes
were also found in skeletal muscle [24]. In addition, another gene
involved in mitochondrial function, PDK4, has been shown to have
increased methylation in skeletal muscle from T2D patients [25].
Among the known genes associated with genetic risk of T2D some
have been identified with DNA methylation differences between
type 2 diabetic and healthy individuals including INS [26] and
PDX1 [27] in pancreatic islets and FTO, SLC30A8 and TCF7L2 in
leukocytes [28,29]. Furthermore, a recent epigenome-wide asso-
ciation study of pancreatic islets from type 2 diabetic and non-
diabetic deceased individuals found differential methylation in
several genes not previously associated with T2D, including
NIBAN and CHAC1 which are involved in endoplasmic reticulum
stress [30]. Also individuals genetically predisposed to T2D
through a family history of T2D have been shown to have altered
DNA methylation in skeletal muscle, among others in mitogen-
activated protein kinase pathway genes [20].
Applying an epigenome-wide microarray approach in a unique
population of elderly monozygotic twins discordant for T2D, the
present study aimed to examine whether likely acquired changes in
DNA methylation of gene promoters in skeletal muscle and
subcutaneous adipose tissue (SAT) associate with T2D. We
hypothesized that the genomic identity of the twins would
eliminate genetic causes of T2D-related DNA methylation
facilitating the identification of acquired changes in a paired study
design. On the other hand, the difficulty of obtaining biopsy
material from a larger number of the rare T2D-discordant twin
pairs is a limitation of the study.
Results
Subject Characteristics
The study population included 12 Danish monozygotic twin
pairs discordant for T2D (Table 1). Skeletal muscle and abdominal
SAT biopsies were available from 11 and 5 pairs, respectively. The
non-diabetic co-twin had normal glucose tolerance in 2 pairs and
impaired glucose tolerance in 10 pairs (Figure 1A). Insulin
sensitivity, measured as the glucose infusion rate (GIR), was
significantly lower in twins with T2D than in their non-diabetic co-
twins (Figure 1B). In addition, fasting plasma glucose, blood
hemoglobin A1c (HbA1c) and body mass index (BMI) differed
significantly between type 2 diabetic and non-diabetic twins
(Table 1).
Global DNA Methylation Patterns
In skeletal muscle and SAT, the fractions of low methylated
(,25%) CpG sites on the array were 64% and 65%, respectively,
whereas the fractions of highly methylated (.75%) sites were 13%
and 15%. Twins from a pair were relatively similar regarding
DNA methylation in each tissue type (Figure 2A2B), whereas the
intra-individual methylation difference between skeletal muscle
and SAT was considerable (Figure 2C). The intra-pair methylation
differences were slightly larger in skeletal muscle than in SAT.
Twin pair was a significant predictor of overall methylation
pattern in both skeletal muscle (P,0.001) and SAT (P,0.001),
whereas overall methylation did not differ according to diabetes
status (P.0.1). However, in both muscle (P,0.001) and SAT
(P=0.009), twin pair interacted with diabetes status. The
variation, expressed as the standard deviation (SD) of absolute
intra-pair methylation differences, was significantly greater in
repetitive LINE1, D4Z4 and NBL2 DNA sequences than in
promoter regions (SD: 10% points vs. 4% points, P,0.001), but
there was no correlation between the degree of variation in these
regions (r =20.05, P=0.9, Figure 3A). The largest variation was
found in methylation of LINE1 CpG sites (SD: 13% points), and it
correlated positively with the intra-pair differences in BMI
(r = 0.77, P=0.007, Figure 3B) and plasma glucose 2 hours after
an oral glucose tolerance test (OGTT, r = 0.66, P=0.03,
Figure 3C), but not significantly with the intra-pair difference in
GIR (r = 0.52, P=0.2, Figure 3D). The intra-pair variation in
D4Z4, NBL2 and promoter regions did not correlate with
phenotypic differences in BMI, 2-hour glucose and GIR.
Differentially Methylated CpG Sites in Type 2 Diabetes
In the 49 known susceptibility genes for mono- or polygenetic
T2D represented on the microarray, 136 CpG sites were
examined for differential methylation by a candidate approach.
Among these sites, 25 sites located in 17 genes (8 sites in muscle
and 17 sites in SAT) were differentially methylated between type 2
diabetic and non-diabetic twins (Table 2, Figure S1B,D–E). These
candidate genes were CDKN2A, DUSP9, HNF4A, HHEX, KCNQ1,
KLF11, PPARGC1A and SLC30A8 in muscle and ADCY5, CAV1,
CIDEC, CDKN2A, CDKN2B, DUSP9, HNF4A, IDE, IRS1, KCNQ1,
MTNR1B, TSPAN8 and WFS1 in SAT. Two CpG sites in SAT
(CDKN2A and HNF4A) remained statistically significant after
permutation correction for multiple testing (Padj=0.02; Table 2,
Figure S1B,D–E). An explorative analysis of all 26,850 array CpG
sites showed that 789 (3%) sites in muscle and 1,458 (5%) sites in
SAT were differentially methylated (P,0.05) in type 2 diabetic
compared with non-diabetic twins before correction for multiple
testing. These CpG sites were located in 768 genes in muscle and
1,389 genes in SAT. One CpG site in muscle (IL8) and 7 sites in
SAT (ZNF668, HSPA2, C8orf31, CD320, SFT2D3, TWIST1,
DNA Methylation Changes in Type 2 Diabetes
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MYO5A) remained statistically significant after permutation
correction (Padj,0.001; Table 3). None of the CpG sites in
repetitive LINE1, D4Z4 and NBL2 sequences differed significantly
in methylation between type 2 diabetic and non-diabetic twins
(P.0.1).
Validation of Array Data
We have recently validated the Illumina DNA methylation
array’s ability to detect methylation differences of approximately
10% points in paired skeletal muscle biopsies from an overfeeding
intervention study [18]. In the present study, five genes (three in
SAT and two in muscle) with larger absolute methylation
differences (.4% points) were selected for validation of the
microarray data in three twin pairs. Bisulfite sequencing (BS) was
used in SAT for MCF2, HNF4A and FAP, and bisulfite
pyrosequencing (PBS) was used in muscle for PPARGC1A and
SLC30A8. The methylation differences for these genes were
successfully validated (Figure S1).
Pathway Analyses
Ingenuity Pathway Analysis software was used to identify
molecular pathways with a significant proportion of genes having
CpG sites differentially methylated between type 2 diabetic and
non-diabetic twins. The analysis was done on genes with at least
one differentially methylated GpC site based on the uncorrected P-
values. Nine muscle pathways were identified, including inflam-
matory (hepatic fibrosis and IL-6), lipid metabolic (PPARa,
PPARc and sphingolipids) and carbohydrate metabolic (pyruvate
and propanoate) pathways (Table S2). In SAT, one carbohydrate
metabolism and one circadian rhythm signaling pathway had a
significant fraction of genes with methylation changes (Table S2).
Discussion
We have previously used a population of twelve monozygotic
twin pairs discordant for T2D to recognize a considerable non-
genetic contribution to glucose metabolic disturbances in genet-
ically identical individuals [31]. In the present study, we used a
similar twin sample for the investigation of genome-wide common
acquired changes in gene promoter DNA methylation in the
primary insulin responsive tissues, skeletal muscle and SAT. We
found that absolute intra-twin pair methylation differences were
relatively small, and most of them did not link significantly to T2D
after correction for multiple testing. The findings altogether
suggest a modest contribution of acquired DNA methylation
differences in skeletal muscle or SAT to the non-genetic
component of T2D.
It has been demonstrated in a prospective study that DNA
methylation changes occur over time, suggesting an influence by
environmental or stochastic events [12]. A study of monozygotic
and dizygotic twins has provided evidence that such epigenetic
changes are more pronounced in non-CpG island than in CpG
island DNA regions [32]. In addition, a clustering of DNA
methylation changes in families indicated that the susceptibility to
a given epigenetic change may have a genetic component [12]. We
hypothesized that the use of genetically identical twins with its
inherent correction for the genetic influence on both disease
Figure 1. Discordance for oral glucose tolerance and insulin sensitivity in monozygotic twins. A Plasma glucose 120 min after a 75-g oral
glucose load in type 2 diabetic and non-diabetic twins (n=12 pairs, P,0.001). B Glucose infusion rate during a euglycemic-hyperinsulinemic clamp in
type 2 diabetic and non-diabetic twins (n=9 pairs, P= 0.006). Data are presented as mean6standard error of the mean.
doi:10.1371/journal.pone.0051302.g001
Table 1. Characteristics of monozygotic twins discordant for
type 2 diabetes.
Non-diabetic
Type 2
diabetic P
n (male/female) 12 (6/6) 12 (6/6) .
Age (years) 68.367.7 68.367.7 1.0
BMI (kg/m2) 30.266.3 32.366.4 0.02
Fasting plasma glucose
(mmol/l)
6.460.5 10.562.0 ,0.001
Fasting serum insulin (pmol/l) 78.9655.2 95.6652.3 0.3
Blood hemoglobin A1c (%) 6.060.5 7.761.4 0.001
Data are shown as mean6standard deviation.
doi:10.1371/journal.pone.0051302.t001
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phenotype and DNA methylation would represent the ideal design
to evaluate acquired DNA methylation changes associated with
T2D.
We investigated the methylation percentage of 26,850 gene
promoter CpG sites in skeletal muscle and SAT and found that the
majority of these sites were clustered into two groups with either a
low or a high methylation percentage. This indicates a high
concordance of methylation for the DNA copies present in a
biopsy. Furthermore, co-twins showed a greater degree of
similarity in gene promoter methylation than unrelated individ-
uals. The overall promoter methylation did not depend on T2D
status alone, but interestingly it was significantly associated with
the interaction between T2D status and twin pair. This suggests
that, within each pair, T2D-related DNA methylation differences
might exist.
The intra-individual DNA methylation pattern in gene
promoters differed vastly between tissues, proposing that DNA
methylation changes associated with tissue development greatly
exceed changes occurring in the finally differentiated tissue. Thus,
our data support the notion of a major role of genetics as well as
tissue specificity in determining the methylation pattern of gene
promoters in adults. The intra-pair methylation differences were
slightly larger in skeletal muscle than in SAT. This phenomenon
could reflect a greater environmental influence on DNA methyl-
ation in skeletal muscle, but could also be due to a greater diversity
of cell types in this tissue.
Figure 2. Global gene promoter DNAmethylation in monozygotic twins. The DNA methylation was measured as the b-value ranging from 0
(unmethylated) to 1 (completely methylated) at 26,850 CpG sites located in the promoters of 14,279 genes. The plots are shown for a representative
twin pair (#3). A Skeletal muscle (r = 0.95, P,0.001). B SAT (r = 0.97, P,0.001). C Comparison of DNA methylation in SAT and skeletal muscle from the
non-diabetic twin.
doi:10.1371/journal.pone.0051302.g002
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In contrast to gene promoters, we found a considerable intra-
pair variation in methylation of genome-wide repetitive DNA
sequences. We have previously demonstrated that differences in
DNA methylation of non-coding regions are more prominent in
elderly monozygotic twins who have spent less of their lives
together than those having shared the environment for a longer
period [21]. A novel finding of our present study is that the
variation in methylation levels of repetitive LINE1 DNA, which
makes up 17% of the human genome [33], was largest in twin
pairs being different in BMI and 2-hour plasma glucose. This
result provides evidence that epigenetic variation reflects the
degree of dissimilarity between phenotypes of monozygotic twins.
However, in agreement with a recent study of human pancreatic
islet cells [30] we found no specific methylation changes in
repetitive DNA sequences between type 2 diabetic and non-
diabetic individuals.
Despite being relatively small, a number of the intra-pair
methylation differences in gene promoters identified by the
Figure 3. Intra-twin pair variation of DNA methylation in repetitive DNA sequences. The variation is given by the standard deviation (SD)
of the absolute methylation differences between monozygotic twins in skeletal muscle. A SD of methylation differences on all repetitive versus all
promoter CpG sites (r =20.05, P= 0.9). B SD of methylation differences on LINE1 repetitive CpG sites versus absolute difference in BMI (r = 0.77,
P= 0.007). C SD of methylation differences on LINE1 repetitive CpG sites versus absolute difference in 2-hour plasma glucose (r = 0.66, P=0.03). D SD
of methylation differences on LINE1 repetitive CpG sites versus absolute difference in glucose infusion rate (r = 0.52, P= 0.2).
doi:10.1371/journal.pone.0051302.g003
DNA Methylation Changes in Type 2 Diabetes
PLOS ONE | www.plosone.org 5 December 2012 | Volume 7 | Issue 12 | e51302
microarrays were successfully validated by two different bisulfite
sequencing methods. The validation additionally showed that
CpG sites close to the array site were likely to be co-methylated
supporting previous observations [14,17]. Although this technical
validation does not exclude the modest biological differences to
have occurred by chance, it supports the sensitivity of the
microarray to detect methylation differences down to a few
percentage points. Previous studies have reported large methyla-
tion differences between cancer cells and normal cells [15], which
may among others be attributed to the fact that the tumor
comprises a clone of abnormal cells. In the, by comparison,
healthier and non-dividing muscle and SAT tissues of type 2
diabetic individuals, it could be speculated that environmentally
determined methylation changes may take place in only some
cells. Recent studies of IGF2 [34], HNF4A [35] and PPARGC1A
[17,18] methylation in blood or skeletal muscle from individuals
exposed to an adverse intrauterine environment showed that
methylation differences between exposed and unexposed individ-
uals were of a similar size to those found in our study. This was
also the case for reported T2D-associated methylation differences
of PPARGC1A [23], INS [26] and PDK4 [25] in pancreatic islets or
skeletal muscle. mRNA expression of these genes was altered in
T2D and in some cases correlated with DNA methylation [23,26].
However, epigenome-wide DNA methylation profiling studies in
pancreatic islets [30] and skeletal muscle [18] with expression
analysis of a fraction of the differentially methylated genes show
that the relationship between small DNA methylation differences
and gene expression is complicated. Several factors such as
location of the specific DNA methylation site in relation to gene
regulatory regions and co-existence of other regulatory mecha-
nisms complicate the study of smaller methylation differences’
biological impact.
Most known T2D susceptibility gene polymorphisms associate
primarily with b-cell dysfunction making the endocrine pancreas
the likely tissue for T2D-associated DNA methylation changes. A
recent genome-wide study of T2D-associated DNA methylation
differences in a small sample of pancreatic islet biopsies identified
many differentially methylated genes in T2D, but none of the
known susceptibility genes were among these [30]. IRS1 [8] and
PPARGC1A [2] belong to the small group of T2D susceptibility
Table 2. Differentially methylated type 2 diabetes susceptibility genes.
Gene Tissue
CpGs
(changed/
total) Probe target ID
Distance to
TSS
(base pairs)
Type 2
diabetic (%)
Non-diabetic
(%)
Difference
(% points) P Padj
Monogenetic
CAV1 SAT 1/6 cg27242945 295 2.360.5 3.560.3 21.2 0.01 0.7
CIDEC SAT 1/2 cg05684195 168 54.863.4 50.062.4 4.9 0.003 0.3
HNF4A Skeletal muscle 1/2 cg23834593 2521 84.662.8 82.462.3 2.2 0.02 0.8
HNF4A SAT 1/2 cg19717150 437 75.263.8 70.563.7 4.6 0.0003 0.02
KLF11 Skeletal muscle 1/2 cg20389709 621 12.7613.4 9.669.6 3.1 0.04 0.9
Common variety
ADCY5 SAT 1/2 cg13384396 2285 14.262.5 11.762.1 2.6 0.03 1.0
CDKN2A Skeletal muscle 1/9 cg07752420 11.762.9 13.162.3 21.4 0.04 0.9
CDKN2A SAT 2/9 cg10895543 5.460.6 6.060.8 20.6 0.04 1.0
CDKN2A SAT 2/9 cg12840719 12.661.9 16.662.1 24.0 0.0003 0.02
CDKN2B SAT 4/10 cg19481686 52.4612.4 44.769.7 7.7 0.02 0.9
CDKN2B SAT 4/10 cg08390209 54.968.3 50.067.0 4.9 0.008 0.6
CDKN2B SAT 4/10 cg04675937 56.2610.9 48.267.3 8.0 0.03 0.9
CDKN2B SAT 4/10 cg18979223 58.468.8 53.565.5 4.9 0.04 1.0
DUSP9 Skeletal muscle 1/1 cg13915726 321 33.9612.8 24.669.1 9.3 0.01 0.6
DUSP9 SAT 1/1 cg13915726 321 20.0613.4 27.5614.6 27.6 0.009 0.6
HHEX Skeletal muscle 1/2 cg11378840 85 6.462.8 4.361.9 2.0 0.046 0.9
IDE SAT 1/2 cg22812892 247 1.660.2 1.360.1 0.3 0.03 1.0
IRS1 SAT 1/2 cg11620807 122 4.060.3 4.160.4 20.1 0.04 1.0
KCNQ1 Skeletal muscle 1/23 cg17820828 52.1611.1 55.5610.7 23.4 0.04 0.9
KCNQ1 SAT 1/23 cg19728223 18.769.0 11.663.9 7.2 0.05 1.0
MTNR1B SAT 1/2 cg15842276 2141 36.866.9 35.366.9 1.5 0.01 0.7
PPARGC1A Skeletal muscle 1/2 cg04893087 2383 13.966.2 9.064.5 5.0 0.03 0.9
SLC30A8 Skeletal muscle 1/2 cg07459489 2174 69.165.0 73.964.0 24.8 0.01 0.5
TSPAN8 SAT 1/2 cg12965512 2557 46.666.6 39.267.9 7.3 0.04 1.0
WFS1 SAT 1/2 cg09785172 81 1.860.3 2.160.4 20.3 0.04 1.0
The microarray included in total 49 type 2 diabetes candidate genes represented by 136 probes. Each CpG site is identified with Illumina probe target ID. The CpG site
location is given as the base pair distance to transcription start site (TSS) if available. Data are shown as mean6standard deviation. Padj-values are corrected for multiple
testing (136 tests).
doi:10.1371/journal.pone.0051302.t002
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Table 3. Differentially methylated genes.
Subcutaneous adipose tissue
Gene Target ID
Distance to TSS
(base pairs)
Mean type 2 diabetic
(%)
Mean non-diabetic
(%)
Difference
(% points) P Padj
ZNF668 cg09765256 23 3.460.5 2.660.5 0.8 ,0.0001 0
HSPA2 cg01520924 12.161.6 14.861.6 22.7 ,0.0001 0
C8orf31 cg04612566 27 35.166.0 26.965.4 8.1 ,0.0001 0
CD320 cg23963136 266 1.460.4 1.960.3 20.5 ,0.0001 0
SFT2D3 cg11206634 2198 67.963.7 74.563.6 26.6 0.0001 0
TWIST1 cg22498251 2415 10.660.8 12.660.8 21.9 0.0001 0
MYO5A cg23287547 769 2.660.4 3.460.5 20.8 0.0001 0
SULT1A1 cg18530748 22 6.361.2 4.761.3 1.5 0.0001 0.1
PRRX2 cg04713521 618 4.761.1 2.861.1 1.9 0.0002 0.9
TGFA cg07004820 479 3.060.4 4.260.3 21.2 0.0002 0.9
WDR8 cg13501117 60 4.760.5 5.460.5 20.6 0.0002 0.9
ERCC6 cg14343062 504 3.260.7 1.860.6 1.4 0.0003 1.0
HNF4A cg19717150 437 75.263.8 70.563.6 4.6 0.0003 1.0
ZDHHC8 cg25650110 98 4.260.6 5.660.6 21.4 0.0003 1.0
CDKN2A cg12840719 12.661.9 16.662.1 24.0 0.0003 1.0
GNB5 cg14120436 67 36.266.0 43.065.7 26.8 0.0003 1.0
CREBL2 cg09819033 2200 1.760.4 2.560.3 20.8 0.0004 1.0
TMEM79 cg14500718 21283 20.765.1 28.963.9 28.2 0.0004 1.0
VGLL1 cg12384303 2424 58.463.6 69.464.8 211.0 0.0005 1.0
KITLG cg18422443 2148 1.960.4 2.560.5 20.6 0.0005 1.0
Skeletal muscle
Gene Target ID
Distance to TSS
(base pairs) Mean T2D (%)
Mean non-T2D
(%)
Difference
(% points) P Padj
IL8 cg16468729 190 48.167.1 37.368.9 10.8 0.0001 0.0003
GZMB cg08766149 131 85.362.1 88.362.4 23.0 0.0001 0.4
MTUS1 cg22807551 2992 10.463.8 7.863.7 2.6 0.0002 0.4
PNOC cg03642518 354 55.563.5 52.364.1 3.2 0.0004 0.9
PDGFD cg07748540 270 4.861.3 3.460.9 1.5 0.0005 0.9
KLF2 cg04898512 2656 89.761.2 88.261.5 1.5 0.0006 0.9
ZNF160 cg12586262 22 13.562.8 9.961.9 3.6 0.0006 0.9
PCBP3 cg23272214 232 85.862.8 88.162.5 22.3 0.0007 1.0
CDR2 cg23142935 630 3.361.8 2.661.6 0.7 0.0010 1.0
TEKT4 cg05723825 243 54.665.4 59.264.9 24.6 0.0014 1.0
DHCR24 cg10073091 604 13.462.2 15.362.6 22.0 0.0014 1.0
ADAM17 cg24320643 321 14.163.3 11.263.1 2.9 0.0017 1.0
SCARA3 cg26847866 500 52.066.8 61.165.6 29.1 0.0017 1.0
KLHL12 cg04462209 321 3.761.4 2.861.4 0.9 0.0017 1.0
SRPK2 cg00950418 2122 3.561.2 4.561.6 21.1 0.0018 1.0
AMN cg09616556 2348 65.862.9 69.863.0 23.9 0.0018 1.0
FOLR3 cg07676849 21106 58.666.8 50.966.2 7.7 0.0021 1.0
PTPN1 cg15864184 217 10.663.7 7.063.2 3.5 0.0025 1.0
CDH13 cg00806490 295 10.162.7 13.161.5 23.0 0.0026 1.0
PIGR cg02105856 23 38.762.4 30.662.3 8.1 0.0027 1.0
The 20 CpG sites with the lowest P-values for the intra-pair methylation difference between type 2 diabetic and non-diabetic twins are shown for subcutaneous adipose
tissue and skeletal muscle. The total number of differentially methylated CpG sites, without correction for multiple testing, was 1,458 in subcutaneous adipose tissue
and 789 in skeletal muscle. Each CpG site is identified with Illumina probe target ID. The CpG site location is given as the base pair distance to transcription start site
(TSS) if available. Data are shown as mean6standard deviation. Padj-values are corrected for multiple testing (26,850 tests).
doi:10.1371/journal.pone.0051302.t003
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genes which might mediate their effects through insulin resistance
and therefore be relevant in peripheral tissues such as SAT and
skeletal muscle. When the known T2D susceptibility genes
represented on the array were specifically evaluated, we found
that ADCY5, CAV1, CIDEC, CDKN2A, CDKN2B, DUSP9, HNF4A,
IDE, IRS1, KCNQ1,MTNR1B, TSPAN8 andWFS1 had at least one
CpG site differentially methylated between type 2 diabetic and
non-diabetic twins in SAT. In skeletal muscle, CpG sites in
CDKN2A, DUSP9, HNF4A, HHEX, KCNQ1, KLF11, PPARGC1A
and SLC30A8 were differentially methylated. However, only the
maturity-onset diabetes of the young (MODY) gene HNF4A [36]
and the T2D gene CDKN2A [37] in SAT had significant
permutation adjusted P-values. Importantly, the absolute methyl-
ation differences identified were smaller than those predicted to be
found at 80% power, particularly in the adipose tissue samples
obtained from only five twin pairs. This finding contrasts the
methylation differences of ,20–30% points identified in a
similarly sized sample of pancreatic islets from type 2 diabetic
and non-diabetic individuals [30] and could be interpreted as the
endocrine pancreas being indeed the tissue with most pathological
changes in T2D. In addition to the statistical limitation, some of
the differences on low-methylated CpG sites such as in IRS1 had
absolute methylation differences that are probably too small to be
detected reliably by the DNA methylation microarray. The finding
of increased HNF4A methylation in tissues from type 2 diabetic
individuals is interesting considering the recent similar result in
umbilical cord blood leukocytes from newborns with intrauterine
growth restriction [35]. Thus, methylation of this gene could
represent a mechanism linking early intrauterine programming to
development of T2D later in life. Even though the increased
methylation of PPARGC1A in type 2 diabetic individuals was not
significant after correction for multiple testing, the result
corresponds well with previous findings in b-cells [23] and skeletal
muscle from type 2 diabetic patients [24]. To this end, we recently
reported elevated methylation of the PPARGC1A promoter in
skeletal muscle from lean and otherwise healthy young men born
with low birth weight. Moreover, five days of high-fat, high-calorie
feeding increased PPARGC1A promoter methylation in healthy
men with normal birth weight [17]. Thus, increased methylation
of PPARGC1A in skeletal muscle seems to be a consistent finding in
patients with overt T2D as well as in individuals at risk of
developing T2D. The recently discovered T2D susceptibility gene,
DUSP9, is another gene which could be important to insulin
resistance. It encodes mitogen-activated kinase phosphatase-4
which counteracts stress-induced insulin resistance [38]. Interest-
ingly, this gene had methylation changes of 829% points
dependent on tissue which was among the largest found on the
array.
The combination of small absolute methylation differences and
a relatively small sample size made it difficult to identify
statistically significant associations between methylation changes
and T2D by an explorative approach. We found 789 and 1,458 of
26,850 CpG sites which were differentially methylated in skeletal
muscle and SAT, respectively. These approximately 5% of the
CpG sites investigated could be chance findings, and the fact that
only a few CpG sites remained significant after correction for
multiple testing contributes to this interpretation of the results.
Genes for which the permutation corrected P-values were
significant included IL8 in muscle and TWIST1 in SAT. The
inflammatory cytokine IL-8 is expressed in among others skeletal
muscle in response to exercise [39], and the transcription factor
Twist1 regulates expression of inflammatory cytokines in adipo-
cytes [40].
Molecular pathway analyses were used to examine whether the
768 muscle and 1,458 SAT genes which, based on the explorative
analysis, were most likely to have DNA methylation changes
belonged to specific functional pathways. Since the methylation
differences in the vast majority of these genes were not significant
after correction for multiple testing the results should be
interpreted cautiously. We found the genes in muscle to be
predominantly involved in inflammation, lipid metabolism, and
carbohydrate metabolism. Low-grade inflammation is considered
to be an important mechanism in insulin resistance [41], and the
lipid metabolic regulators PPARa, PPARc, as well as PGC-1a
have been shown to play a role in the regulation of insulin
sensitivity [42–44]. In SAT, carbohydrate metabolism and
circadian rhythm signaling pathways had a significant fraction of
genes differentially methylated between type 2 diabetic and non-
diabetic individuals. Recent studies have shown that genetic
variation in MTNR1B and CRY2, involved in circadian signaling,
associate with T2D or related metabolic traits [3,45]. Interestingly,
both of these genes were differentially methylated in SAT from
type 2 diabetic and non-diabetic twins.
In conclusion, common skeletal muscle and adipose tissue gene
promoter DNA methylation differences between monozygotic
twins discordant for T2D were small, but a number of the
differences were found in known T2D-related candidate genes.
Larger study groups, preferably with longitudinal sample collec-
tion and methylation analysis of the entire promoter are needed to
replicate the findings in these genes.
Research Design and Methods
Study Participants
Twelve 53–80 year-old monozygotic twin pairs discordant for
T2D were recruited through the Danish Twin Registry, University
of Southern Denmark. Six pairs had participated in a previous
study [46] where discordance for T2D was recognized based on an
OGTT. These pairs were reexamined for the present study. The
additional six pairs were recruited based on information from the
Twin Registry about known T2D. All study participants had
provided written informed consent, and the study was approved by
the regional Ethical Committee (Southern Denmark, http://
komite.regionsyddanmark.dk) and conducted in accordance with
the principles of the Helsinki Declaration.
Clinical Examination
Height and weight were measured in light weight clothes for
calculation of BMI. Discordance for T2D was verified by a 75-g
OGTT. Insulin sensitivity was measured in a subpopulation (n=9
pairs) by a euglycemic-hyperinsulinemic clamp (40 mU
m22 min21) and expressed as the mean GIR during the last
30 min of the clamp period.
Biopsies
Biopsies were excised under local anesthesia (lidocaine) from the
vastus lateralis muscle (n=11 pairs) and from abdominal SAT
(n=5 pairs) using a Bergstro¨m needle with suction applied. The
tissue samples were frozen immediately in liquid nitrogen and
stored at 280uC until processed further.
DNA Extraction
Genomic DNA was extracted from the biopsies using a DNeasy
Blood & Tissue Kit (Qiagen, Hilden, Germany), and DNA
concentrations were determined by a Quant-IT PicoGreen
dsDNA Kit (Invitrogen, Carlsbad, CA).
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DNA Methylation Microarrays
Methylation was assessed at 27,578 CpG sites primarily located
close to the transcription start site (TSS) in the promoters of
14,475 genes using 12-sample Infinium HumanMethylation27
Bead Chips (Illumina, San Diego, CA). 600 ng DNA was bisulfite-
treated to deaminate unmethylated cytosines to uracil using an EZ
DNA Methylation Kit (Zymo Research, Orange, CA). The array
was scanned by a BeadArray Reader (Illumina), and intensity data
analyzed using GenomeStudio software (version 2011.1, Illumina).
Internal array controls verified the hybridization, staining and
washing procedures. The methylation status on each CpG site was
expressed as the b-value which is the ratio between fluorescent
signal from converted and preserved sequence bead types. DNA
samples from twin pairs were analyzed on the same bead chip to
eliminate a possible influence of batch effect in the subsequent
paired statistical analyses. Due to reruns four pairs of muscle
samples were separated on different chips. Batch effect in the data
set was examined for by unsupervised cluster analysis using MeV
software (version 4.5, available at http://www.tm4.org) and scatter
plots of principal components 1 and 2. Since only minimal batch
effect was found compared to clustering according to twin pair and
sex, no further normalization of the b-values was performed. b-
values for probes where intensity did not exceed the background
level (P$0.05) were omitted (in average 54 b-values per muscle
sample and 23 b-values per SAT sample). All probes were
examined for unique genome alignment and for SNPs affecting the
CpG site using NCBI human genome build 36 FASTA files and
custom PERL (version 5.10.1, available at http://www.perl.org)
scripts. For the analysis of unique alignment, two ‘‘bisulfite-
treated’’ reference genomes were constructed replacing cytosine by
thymine as forward strand reference, and replacing guanine by
adenine as reverse strand reference. The unmethylated bead type
probe sequences were compared to these reference genomes using
the BLAT algorithm [47]. For the SNP analysis, Illumina’s
annotation data were used to mark each target region in a
reference genome containing dbSNP build 130 information. All
corresponding SNP-masked sequences were extracted and
screened for SNPs. 494 probes were excluded due to multiple
alignments, and additionally 234 were excluded due to SNP in the
CpG site. The microarray data have been deposited in the Gene
Expression Omnibus (GEO) database (http://www.ncbi.nlm.nih.
gov/geo, accession number GSE38291) complying with the
Minimum Information About a Microarray Experiment (MIAME)
guidelines.
Validation and Methylation of Repetitive DNA
Array data were validated in three genes in SAT by BS and in
two genes in skeletal muscle by BPS. DNA methylation of LINE1
(interspersed repeat with 8 CpG sites), D4Z4 (tandem repeat with
9 CpG sites) and NBL2 (tandem repeat with 8 CpG sites)
sequences was measured by BPS in the muscle samples. The
repetitive distribution of these sequences means that the DNA
methylation measured is a genome-wide average value.
Bisulfite sequencing. 1 mg DNA was bisulfite-treated as
described previously [48]. Oligonucleotide primers (Sigma-Al-
drich, St. Louis, MO) were designed using Methyl Primer Express
Software (Applied Biosystems, Foster City, CA) to make the PCR
amplicons cover approximately five CpG sites, including the site
analyzed on the array (Table S1). The PCR product was separated
on a 2% agarose gel, and specific DNA bands were cut and
purified by a GFX PCR DNA and Gel Band Purification Kit (GE
Healthcare, Buckinghamshire, UK). The specific amplicons were
cloned in E. coli using the pGEM-T vector system (Promega,
Madison, WI). Twelve positive colonies were collected, and
plasmid DNA was purified by a Perfectprep Plasmid 96 Vac Kit
(Eppendorf, Hamburg, Germany). The plasmid DNA insert was
finally sequenced on an ABI 3100 system (Applied Biosystems).
The number of methylated and unmethylated clones was counted,
and the methylation percentage calculated as the average
methylation of all CpG sites in the amplicon.
Bisulfite pyrosequencing. BPS was performed on bisulfite-
treated DNA using a PyroMark MD pyrosequencing system
(Biotage, Uppsala, Sweden). Specific pyrosequencing primers were
designed to amplify as many CpGs as conditions permitted (1 to 9
sites) using Assay Design Software (version 1.0.6, Biotage, Table
S1). The cytosine methylation percentage was evaluated with the
Pyro Q-CpG program (version 1.0.9, Biotage).
Statistical Methods
The statistical analyses were performed using R software
(version 2.11.1, available at http://www.r-project.org). b-values
are shown in percentages and differences given in percentage point
change (type 2 diabetic twin 2 non-diabetic twin). The differences
were examined for normality using the Shapiro-Wilk normality
test. Only 6% of the CpG sites in adipose tissue and 9% of the
CpG sites in skeletal muscle had P-values,0.05 suggestive of non-
normally distributed differences, and therefore parametric statistics
were applied.
Analysis of twin pair similarity. An ANOVA including
methylation of all microarray CpG sites as response variable and
twin pair, diabetes status and their interaction as explanatory
variables was used to evaluate the effect of twin pairs on the overall
DNA methylation similarity. For correlation analyses the intra-
pair variation in promoter or repetitive DNA methylation was
expressed as the SD for the absolute differences.
Analysis of differential methylation by candidate gene
approach. All monogenic and confirmed common variety T2D
susceptibility genes reviewed by O’Rahilly [1] were examined for
differential methylation if represented on the array. In addition,
KCNQ1 [6] and KLF11 [7] as well as the newly discovered genes,
ADCY5, GCK, GCKR, PROX1, DUSP9, HMGA2, KLF14, TP53INP1
and RBMS1 [3–5] were included. PPARGC1A [2] was included
due to an a priori hypothesis of altered DNA methylation in type 2
diabetic individuals [23,24]. Thus, the genes analyzed were
ABCC8, ADAMTS9, ADCY5, AGPAT2, AKT2, BSCL2, CAMK1D,
CAV1, CDC123, CDKAL1, CDKN2A, CDKN2B, CEL, CIDEC,
DUSP9, HHEX, HMGA2, HNF1A, HNF1B, HNF4A, GCK, GCKR,
IDE, IGF2BP2, INS, INSR, IRS1, JAZF1, KCNJ11, KCNQ1, KIF11,
KLF11, KLF14, LGR5, LMNA, MTNR1B, NEUROD1, NOTCH2,
PDX1, PPARG, PPARGC1A, PROX1, RBMS1, SLC30A8, TBC1D4,
TCF7L2, TP53INP1, TSPAN8, and WFS1. These 49 genes were
represented by 136 probes. Comparisons between type 2 diabetic
and non-diabetic twins were performed by paired t-tests. Two-
sided P,0.05 was considered statistically significant, and the P-
values were corrected for multiple testing, Padj, using the Westfall-
Young resampling method [49]. 10,000 simulations with permu-
tations of the sample labels were used to sample the null
distribution.
Analysis of differential methylation by explorative
approach. Comparisons between type 2 diabetic and non-
diabetic twins were performed for all 26,850 array CpG sites by
paired t-tests, and the P-values were corrected for multiple testing
as described above.
Statistical power calculations. The study population size
was limited to the maximal number of Danish T2D discordant
monozygotic twin pairs that could be recruited in a 10-year
period. From previous studies of PPARGC1A, DNA methylation
differences of ,5% points with ,5% points SD have been
DNA Methylation Changes in Type 2 Diabetes
PLOS ONE | www.plosone.org 9 December 2012 | Volume 7 | Issue 12 | e51302
identified [17,23]. Given the 11 pairs of muscle biopsies and a
fixed SD of 5% points the study allowed detecting a 5% point
methylation difference in a single paired t-test at 80% power. The
size of the minimal detectable differences would increase to 10% in
the candidate gene analysis (136 t-tests) and 17% in the genome-
wide analysis (26,850 t-tests) when applying Bonferroni correction.
For the only 5 pairs of adipose tissue biopsies the similar minimal
detectable differences would be 8%, 31% and 117% for single
CpG site analysis, candidate gene study and hypothesis-free
approach, respectively.
Validation of methylation array data. Differences in DNA
methylation levels between three pairs of type 2 diabetic and non-
diabetic twins obtained by BS or BPS were analyzed by paired t-
test. Based on the a priori hypothesis of replicating array findings
one-sided P,0.05 was considered statistically significant.
Molecular pathway analyses. Differentially methylated
genes identified by the explorative approach, without correction
for multiple testing, were included in Ingenuity Pathway Analyses
(version 7.5, Ingenuity Systems, Redwood City, CA). This software
recognized the pathways from the Ingenuity Pathways Analysis
library of canonical pathways (81 metabolic and 283 signaling)
which contained a significant fraction of differentially methylated
genes. Only genes represented on the array were used for the
reference pathways. Fischer’s exact test was used to calculate the
probability that the association between the differentially methyl-
ated genes and the canonical pathway was explained by chance.
These P-values were not corrected for multiple testing.
Supporting Information
Figure S1 Validation of array data. The average DNA
methylation in the gene promoter area surrounding the array site
measured by bisulfite sequencing (BS) or bisulfite pyrosequencing
(BPS) is indicated in type 2 diabetic (black bars) and non-diabetic
(white bars) twins. Three twin pairs were included in the
validations. One-sided P-values are shown for the difference
between type 2 diabetic and non-diabetic twins measured by BS or
BPS. Gene diagrams, including the number of methylated (black)
and unmethylated (white) clones for each CpG site in the
amplicon, are shown for BS results. A MCF2 +226 base pairs
from transcription start site (TSS) in subcutaneous adipose tissue
(P,0.001), B HNF4A 2521 base pairs from TSS in subcutaneous
adipose tissue (P=0.04), C FAP +80 base pairs from TSS in
subcutaneous adipose tissue (P,0.001), D PPARGC1A 2383 base
pairs from TSS in skeletal muscle (P=0.006), E SLC30A8 2174
base pairs from TSS in skeletal muscle (P=0.002). Data are
presented as mean6standard error of the mean.
(PDF)
Table S1 Primer sequences.
(DOC)
Table S2 Molecular pathways with a significant frac-
tion of differentially methylated genes. No overlap denotes
the fraction of genes in each pathway which was not represented
on the array. The direction of methylation change in type 2
diabetic versus non-diabetic twins is indicated by arrows (q:
increased, Q: decreased).
(DOC)
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